Literature DB >> 33655712

SIRT3 promotion reduces resistance to cisplatin in lung cancer by modulating the FOXO3/CDT1 axis.

Yang Cao1, Ping Li2, Haicun Wang1, Lei Li1, Quanwang Li3.   

Abstract

BACKGROUND: Cisplatin is an extensively used chemotherapy agent for lung cancer, but its drug resistance serves as a huge obstacle for chemotherapy failure of lung cancer patients. Hence, researchers aimed to determine role of sirtuin 3 (SIRT3) considering its action in cisplatin resistance of lung cancer.
METHODS: The expression patterns of SIRT3, FOXO3, and CDT1 were determined using RT-qPCR and Immunoblotting in lung cancer. Immunofluorescence and Co-IP were adopted to detect co-localization and interaction of FOXO3 and CDT1. Loss- and gain-function assays were conducted to determine roles of SIRT3, FOXO3, and CDT1 in resulting pathological changes, while biological behavior of cells was determined using a combination of CCK-8, flow cytometry, colony formation, and Transwell assays. The effects of SIRT3 and CDT1 were determined in the nude mice xenografted with the tumor. The proliferation-, angiogenesis-, and apoptosis-associated factors levels were determined using Immunoblotting.
RESULTS: SIRT3, FOXO3, and CDT1 expression was suppressed in the lung cancer tissues and cells. FOXO3 positively regulates the CDT1 expression pattern and SIRT3 elevation inhibits FOXO3 at the acetylated level, thus, elevating FOXO3 expression. The elevation of SIRT3, FOXO3, or CDT1 inhibited cell cisplatin resistance of lung cancer cells as well as inhibited viability, proliferation, and invasion in vitro. In vivo experiments, SIRT3 depletion elevated Ki-67 and VEGFA levels, but downregulated cleaved caspase 3 level.
CONCLUSION: Collectively, overexpressed SIRT3 elevates expression of FOXO3a/CDT1 axis, thus, contributing to enhanced sensitivity of lung cancer cells.
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Forkhead box O3a; chromatin licensing and DNA replication factor 1; cisplatin; lung cancer; sirtuin 3

Mesh:

Substances:

Year:  2021        PMID: 33655712      PMCID: PMC7926010          DOI: 10.1002/cam4.3728

Source DB:  PubMed          Journal:  Cancer Med        ISSN: 2045-7634            Impact factor:   4.452


  25 in total

1.  Regulation of cell cycle progression by forkhead transcription factor FOXO3 through its binding partner DNA replication factor Cdt1.

Authors:  Yiru Zhang; Yuqian Xing; Lei Zhang; Yang Mei; Kazuo Yamamoto; Tak W Mak; Han You
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-26       Impact factor: 11.205

2.  Ganoderic acid DM induces autophagic apoptosis in non-small cell lung cancer cells by inhibiting the PI3K/Akt/mTOR activity.

Authors:  Junbo Xia; Lujun Dai; Liusheng Wang; Jing Zhu
Journal:  Chem Biol Interact       Date:  2019-12-23       Impact factor: 5.192

3.  Peptide-Based Autophagic Gene and Cisplatin Co-delivery Systems Enable Improved Chemotherapy Resistance.

Authors:  Yao-Xin Lin; Yi Wang; Hong-Wei An; Baowen Qi; Junqing Wang; Lei Wang; Jinjun Shi; Lin Mei; Hao Wang
Journal:  Nano Lett       Date:  2019-04-03       Impact factor: 11.189

4.  SIRT3 inhibits prostate cancer metastasis through regulation of FOXO3A by suppressing Wnt/β-catenin pathway.

Authors:  Rong Li; Yizhou Quan; Weiliang Xia
Journal:  Exp Cell Res       Date:  2018-02-06       Impact factor: 3.905

5.  FOXO3 encodes a carcinogen-activated transcription factor frequently deleted in early-stage lung adenocarcinoma.

Authors:  Oliver R Mikse; Daniel C Blake; Nathan R Jones; Yuan-Wan Sun; Shantu Amin; Carla J Gallagher; Philip Lazarus; Judith Weisz; Christopher R Herzog
Journal:  Cancer Res       Date:  2010-07-14       Impact factor: 12.701

6.  NF-κB-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance.

Authors:  Ching-Feng Chiu; Yi-Wen Chang; Kuang-Tai Kuo; Yu-Shiuan Shen; Chien-Ying Liu; Yang-Hao Yu; Ching-Chia Cheng; Kang-Yun Lee; Feng-Chi Chen; Min-Kung Hsu; Tsang-Chih Kuo; Jui-Ti Ma; Jen-Liang Su
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-18       Impact factor: 11.205

7.  SIRT3 interactions with FOXO3 acetylation, phosphorylation and ubiquitinylation mediate endothelial cell responses to hypoxia.

Authors:  Anne H-H Tseng; Li-Hong Wu; Shyan-Shu Shieh; Danny Ling Wang
Journal:  Biochem J       Date:  2014-11-15       Impact factor: 3.857

8.  Lung tumourigenesis in a conditional Cul4A transgenic mouse model.

Authors:  Yi-Lin Yang; Ming-Szu Hung; Yang Wang; Jian Ni; Jian-Hua Mao; David Hsieh; Alfred Au; Atul Kumar; David Quigley; Li Tai Fang; Che-Chung Yeh; Zhidong Xu; David M Jablons; Liang You
Journal:  J Pathol       Date:  2014-06       Impact factor: 7.996

9.  Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway.

Authors:  Mingjing Shen; Zhonghua Xu; Weihua Xu; Kanqiu Jiang; Fuquan Zhang; Qifeng Ding; Zhonghen Xu; Yongbing Chen
Journal:  J Exp Clin Cancer Res       Date:  2019-04-08

10.  Adjudin synergizes with paclitaxel and inhibits cell growth and metastasis by regulating the sirtuin 3-Forkhead box O3a axis in human small-cell lung cancer.

Authors:  Xue Wang; Qingyu Zeng; Ziming Li; Xiao Yang; Weiliang Xia; Zhiwei Chen
Journal:  Thorac Cancer       Date:  2019-02-18       Impact factor: 3.500

View more
  4 in total

Review 1.  The Role and Therapeutic Perspectives of Sirtuin 3 in Cancer Metabolism Reprogramming, Metastasis, and Chemoresistance.

Authors:  QingYi Zhao; Jing Zhou; Feng Li; Sen Guo; Liang Zhang; Jing Li; Qin Qi; Yin Shi
Journal:  Front Oncol       Date:  2022-06-27       Impact factor: 5.738

2.  Long non-coding RNA-PCGEM1 contributes to prostate cancer progression by sponging microRNA miR-129-5p to enhance chromatin licensing and DNA replication factor 1 expression.

Authors:  Qiao Fu; Fangfang Wang; Jun Yang; Wei Sun; Zhi Hu; Lv Xu; Hao Chu; Xiao Wang; Wei Zhang
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

3.  Dysregulation of SIRT3 SUMOylation Confers AML Chemoresistance via Controlling HES1-Dependent Fatty Acid Oxidation.

Authors:  Yirong Zhang; Yajie Shen; Weiqing Wei; Wenhan Wang; Daiji Jiang; Yizhuo Ren; Zijing Peng; Qiuju Fan; Jinke Cheng; Jiao Ma
Journal:  Int J Mol Sci       Date:  2022-07-27       Impact factor: 6.208

4.  Study on the Evaluation of Lung Cancer Patients from the Three Aspects of Emotion.

Authors:  Panpan Li; Jiangli Yu; Xiaohui Wang; Xiaonan Pang; Chengjing Yu; Yingqiong Xu
Journal:  Contrast Media Mol Imaging       Date:  2022-09-15       Impact factor: 3.009

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.